Frontlight ResearchEarly access
Taking people in GermanyPhase 2
Tests shorter versus longer combination drug therapy for recurrent head and neck cancer
Tests combined cancer drugs in adults with head and neck cancer that has returned.
Key facts
- Who runs it
- Charite Universitaetsmedizin Berlin KöR
- Where
- Aachen, Berlin, Essen, Hanover, and Stuttgart, GermanySee the 5 sites
- Trial code
- EU 2025-521738-27-00
- U1111-1326-5486
- Registry title
- A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 126 people, planned
- Started
- 15 Dec 2025
- Expected to end
- 29 Jan 2030
- Type of study
- Interventional
- Record updated
- 11 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with head and neck squamous cell cancer that came back or spread and cannot be treated to remove it. It compares two versus four cycles of a four-drug combination.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Head and neck squamous cell carcinoma that came back or spread, with disease that can be measured on scans (RECIST 1.1). Cancer starting in the nasopharynx or of unknown origin cannot join.
- Earlier treatment
- No earlier drug treatment for the recurrent or spread disease. Earlier chemoradiation or drug treatment for locally advanced disease is allowed if finished more than 6 months before. Side effects from it must be gone or mild (grade 1 at most).
- Biomarker or test result
- PD-L1 CPS score of 1 or higher. For cancer of the throat behind the mouth (oropharynx), a p16 test showing HPV link is needed.
Main reasons for not taking part
- Active or untreated cancer spread to the brain or its lining
- Active infection needing treatment, or HIV, hepatitis B or hepatitis C that is not controlled as the record sets out
- Active autoimmune disease needing drugs that lower the immune system
- Earlier organ or stem-cell transplant
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Patients (male, female, divers) must be ≥18 years of age
- Measurable disease based on RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
- No prior systemic therapy administered in the recurrent or metastatic setting prior chemoradiation for locally advanced disease is allowed if completed at least 6 months before randomization. Systemic therapy, including anti-PD-(L)1 therapy, given as part of multimodal treatment for locally advanced disease is allowed and must be completed >6 months prior to signing consent. Any toxicity resulting from previous systemic treatment must be resolved or shall not exceed grade 1 based on CTCAE v.5 grading
- Availability of archived tumor tissue (Block or at least 20 slides)
- Documentation of disease progression following curative intended treatment
- Written informed consent obtained from the patient prior to any study-specific procedures
- Patient is willing to assess Quality of Life throughout the study
- Adequate hematologic function: Absolute neutrophil count (ANC) ≥1,500/μL, platelets ≥100,000/μL, hemoglobin ≥9.0 g/dL
- Adequate hepatic function: Total bilirubin ≤1.5 × the upper limit of normal (ULN), AST and ALT ≤2.5 × ULN
- Adequate renal function: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min as calculated by the Cockcroft-Gault formula
- Women of childbearing potential (WOCBP) must have a negative pregnancy test and agree to use highly effective contraception throughout the study and for at least 30 days after last treatment administration. Men must agree to use adequate contraception. a) For female participants: i) Confirmed post-menopausal state (defined as amenorrhea for at least 12 months), or ii) For women of childbearing potential (WOCBP): (1) Negative serum pregnancy test (β‐hCG) before inclusion/randomization, and (2) Practicing a highly effective birth control method (failure rate of less than 1%): I. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral/intravaginal/ transdermal), or II. progestogen-only hormonal contraception associated with inhibition of ovulation (oral/injectable/implantable), or III. intrauterine device (IUD), or IV. intrauterine hormone-releasing system (IUS), or V. bilateral tubal occlusion, or VI. vasectomised partner, or VII. heterosexual abstinence
- Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that is not amenable to curative treatment. Primary tumors in the nasopharynx or cancer of unknown origin are excluded
- Local PD-L1 CPS results for stratification with an expression score ≥1
- Local p16 IHC indicating HPV association for oropharyngeal primary tumor
Who cannot take part
- Participation in another clinical trial with an investigational product within 4 weeks prior to randomization or until End of trial of the individual participant
- Organ transplantation: Prior organ transplantation including allogenic stem-cell transplantation
- Cardiovascular disease: Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication
- Vaccination: Vaccination within 4 weeks of the first dose of study medication and while on trials is prohibited except for administration of inactivated vaccine
- Severe uncontrolled systemic disease (e.g., severe chronic obstructive pulmonary disease, severe cardiac disease)
- Participant has any history of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
- Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured
- History of severe hypersensitivity reactions to monoclonal antibodies or any components of the study drugs
- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Active autoimmune disease requiring systemic immunosuppressive treatment. Patients with controlled autoimmune disease not requiring systemic immunosuppressive treatment including diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible. Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).”
- Infectious diseases as below: a. Active infection requiring systemic treatment, b. Known HIV infection, unless the participant can meet all the following criteria: i) Documented evidence of plasma HIV-1 RNA persistently <50 copies)/mL confirmed ≤3 months prior to AND at Screening; unless undetectable viral load is defined differently by local guidelines and agreed with the spnsor. In the >3 to 12 months prior to Screening, plasma HIV-1 RNA consistently <50 copies/mL is required; if single/isolated increases ≥50 copies/mL occurred and are thought not to be persistent andnot associated with antiretroviral resistance as per investigator assessment, the participant would be eligible AND ii) CD4 cell count ≥350 cells/mm3 over past 12 months and at Screening (and no measurement <350 cells/mm3 during that period) AND iii) Must be on an uninterrupted combination antiretroviral therapy regimen for at least 3 months prior to Screening, with combination antiretroviral therapy regimen consistent with locally recommended guidelines c. Participants who test positive for HCV antibodies and have positive HCV RNA. d. Untreated chronic hepatitis B or chronic HBV inactive carriers with HBV DNA >500 IU/mL (or >2500 copies/mL) at screening. Patients with chronic hepatitis B (HBsAg-positive) are eligible if they are on adequate antiviral prophylaxis (e.g., entecavir or tenofovir) per local standards and agree to continued monitoring
- Laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
- Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
- Pregnant or breastfeeding women
- Patients who are institutionalized by order of court or public authority
- Patients who might be dependent on the sponsor/ investigator or the trial site
- Patients not willing to assess QoL at the defined timepoints
Where in Germany
- Universitaetsklinikum Aachen AöRAachen, GermanyTaking people
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- Universitaetsklinikum Essen (AoR)Essen, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Klinikum Der Landeshauptstadt Stuttgart gKAöRStuttgart, GermanyTaking people
About the trial
What the trial wants to find out
To compare the quality of life at 18 weeks after treatment initiation between two cycles and four cycles of combination therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and Docetaxel in Patients with Recurrent Metastatic Head and Neck Cancer - AVETUX-HN
- Plain-language title
- Tests shorter versus longer combination drug therapy for recurrent head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 June 2026